9 results
Summary of characteristics of Platelet Aggregation Inhibitors

#AntiPlatelet #Inhibitors #Pharmacology #Table #Overview #Interactions #Pharmacology #Cardiology
#AntiPlatelet #Inhibitors ... #Pharmacology # ... Table #Overview #Interactions ... #Pharmacology # ... Cardiology
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
SGLT2 Inhibitors ... - Pharmacology ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
DPP-4 Inhibitors ... - Pharmacology ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors ... Stimulates Insulin, Inhibits ... Renal #Dosing #Pharmacology ... Management #Diabetes #DM2 ... #Endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
SGLT2 Inhibitors ... SGLT2 inhibitors ... #Pharmacology # ... Medications #DM2 ... #Diabetes #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Sulfonylurea, TZD, DPP-4 inhibitor ... α-glucosidase inhibitor ... Diabetes #Mellitus #DM2 ... #Medications #pharmacology ... comparison #table #endocrinology
Clinically Significant Cardiovascular Drug-Drug Interactions With OTC Supplements and Herbal Products
Angiotensin-Converting Enzyme Inhibitors (ACEIs)
 • Night-blooming
Cardiovascular Drug-Drug Interactions ... Angiotensin-Converting Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... supplementals #herbal #pharmacology ... #DDI #table #cardiology
Allopurinol Pharmacology Summary

Xanthine oxidase inhibitor blocking the formation of new uric acid
Initiate 1-2 days prior to
Allopurinol Pharmacology ... Xanthine oxidase inhibitor ... Dosing: 100 mg/m2 ... hypersensitivity Drug interactions ... #pathophysiology
Management of Anthracyclines and HER2 Antagonist Cardiotoxicity
Anthracyclines cause cardiomyopathy:
 ✖ Reduction in left ventricular ejection fraction
, 350 mg/m2, and ... system (RAAS) inhibitor ... prophylactic RAAS inhibitor ... Cardiotoxicity #cardiology ... #oncology #pharmacology